
Personalis PSNL
€ 13.95
0.06%
Personalis Betriebsaufwand | PSNL
Betriebsaufwand Jährlich Personalis
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 44.5 M | 25.6 M | 19.8 M | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 44.5 M | 19.8 M | 30 M |
Betriebsaufwand anderer Aktien in der Diagnostik & Forschung
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Anixa Biosciences
ANIX
|
9.98 M | $ 2.6 | 1.45 % | $ 84.4 K | ||
|
Biodesix
BDSX
|
116 M | $ 28.56 | 3.1 % | $ 216 M | ||
|
Biomerica
BMRA
|
5.68 M | $ 2.37 | 3.04 % | $ 6.91 M | ||
|
BioNano Genomics
BNGO
|
41.3 M | $ 1.51 | 17.29 % | $ 8.22 M | ||
|
Burning Rock Biotech Limited
BNR
|
726 M | $ 12.52 | 7.19 % | $ 132 M | ||
|
Bioventus
BVS
|
217 M | $ 13.2 | 1.54 % | $ 879 M | ||
|
CareDx, Inc
CDNA
|
411 M | $ 53.55 | 1.73 % | $ 2.85 B | ||
|
Celcuity
CELC
|
172 M | $ 82.58 | 1.04 % | $ 3.86 B | ||
|
Charles River Laboratories International
CRL
|
607 M | $ 273.41 | 0.19 % | $ 13.6 B | ||
|
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M | ||
|
Syneos Health
SYNH
|
4.12 B | - | - | $ 4.46 B | ||
|
Motus GI Holdings
MOTS
|
19.1 M | - | -34.28 % | $ 263 K | ||
|
Renalytix AI plc
RNLX
|
29.8 M | - | 5.66 % | $ 22.7 M | ||
|
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | ||
|
Psychemedics Corporation
PMD
|
8.99 M | - | -1.84 % | $ 15.3 M | ||
|
Quotient Limited
QTNT
|
119 M | - | -11.32 % | $ 1.1 M | ||
|
T2 Biosystems
TTOO
|
38.2 M | - | -39.35 % | $ 313 K | ||
|
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | ||
|
Meridian Bioscience
VIVO
|
134 M | - | - | $ 1.49 B | ||
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M | ||
|
DarioHealth Corp.
DRIO
|
49.3 M | $ 6.78 | 0.44 % | $ 27 M | ||
|
Co-Diagnostics
CODX
|
50.6 M | $ 0.94 | 2.7 % | $ 1.25 M | ||
|
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.46 B | $ 247.08 | 0.16 % | $ 27.4 B | ||
|
Fulgent Genetics
FLGT
|
222 M | $ 21.63 | 1.64 % | $ 666 M | ||
|
Guardant Health
GH
|
226 M | $ 174.9 | 1.33 % | $ 21.9 B | ||
|
Castle Biosciences
CSTL
|
59.5 M | $ 35.48 | 0.03 % | $ 1.03 B | ||
|
ICON Public Limited Company
ICLR
|
408 M | $ 173.94 | 0.86 % | $ 13.6 B | ||
|
IDEXX Laboratories
IDXX
|
1.3 B | $ 513.62 | 0.57 % | $ 41.3 B | ||
|
Illumina
ILMN
|
2.06 B | $ 228.93 | 2.99 % | $ 35.5 B | ||
|
IQVIA Holdings
IQV
|
2.94 B | $ 268.82 | 0.12 % | $ 46.2 B | ||
|
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 324.51 | 0.17 % | $ 27 B | ||
|
Lantheus Holdings
LNTH
|
123 M | $ 100.54 | 0.03 % | $ 6.79 B | ||
|
Medpace Holdings
MEDP
|
118 M | $ 616.44 | 0.07 % | $ 17.8 B | ||
|
Mettler-Toledo International
MTD
|
1.01 B | $ 1 378.69 | 3.63 % | $ 28.4 B | ||
|
Danaher Corporation
DHR
|
6.71 B | $ 208.36 | 0.75 % | $ 148 B | ||
|
Myriad Genetics
MYGN
|
964 M | $ 3.86 | 0.9 % | $ 357 M | ||
|
ENDRA Life Sciences
NDRA
|
5.76 M | $ 5.3 | 1.13 % | $ 4.17 M | ||
|
NeoGenomics
NEO
|
430 M | $ 18.94 | 0.26 % | $ 2.43 B | ||
|
Brainsway Ltd.
BWAY
|
29.2 M | $ 13.46 | 0.52 % | $ 457 M | ||
|
National Research Corporation
NRC
|
38.5 M | $ 22.05 | 0.41 % | $ 494 M | ||
|
Natera
NTRA
|
258 M | $ 345.34 | 1.69 % | $ 47.2 B | ||
|
OPKO Health
OPK
|
187 M | $ 1.61 | 2.55 % | $ 1.21 B | ||
|
Pacific Biosciences of California
PACB
|
600 M | $ 1.34 | 1.87 % | $ 402 M | ||
|
DexCom
DXCM
|
1.89 B | $ 87.34 | 1.03 % | $ 34.1 B | ||
|
Precipio
PRPO
|
11.9 M | $ 26.66 | 0.59 % | $ 42.8 M | ||
|
RadNet
RDNT
|
1.98 B | $ 75.78 | 0.27 % | $ 5.7 B |